You are seeing these quotes based on previous browsing related to sectors such as
| Latest | Forecast | |
|---|---|---|
| Div Yield | 0.0% | 0.0% |
| Div Cover | n/a | n/a |
| Op Mrgn | -7,882.9% | n/a |
| ROCE | 0.0% |
| Latest | Forecast | |
|---|---|---|
| P/E | -1.2 | 0.0 |
| PEG | 0.0 | -999,999.0 |
| Price / Revenue | 83.3 | 0.0 |
| Price / Book value | 1.9 |
| Latest | Forecast | |
|---|---|---|
| Revenue | -99.6% | 0.0% |
| PBT | 0.0% | n/a |
| EPS | 0.0% | -55.1% |
| DPS | n/a | 0.0% |
| Year Ending | Revenue (£m) |
Pre-tax (£m) |
EPS | P/E | PEG | EPS Growth | Div | Yield |
|---|---|---|---|---|---|---|---|---|
| 2014-09-30 | n/a | -4.26 | -7.60p | 0.0 | 0.0 | n/a | n/a | 0.0% |
| 2015-09-30 | n/a | -8.82 | -14.10p | -7.2 | 0.0 | n/a | n/a | 0.0% |
| 2016-09-30 | n/a | -15.41 | -19.80p | -3.1 | 0.0 | n/a | n/a | 0.0% |
| 2017-09-30 | 30.47 | 1.65 | 1.40p | 23.1 | 0.0 | n/a | n/a | 0.0% |
| 2018-09-30 | 0.13 | -10.15 | -7.00p | -1.2 | 0.0 | n/a | n/a | 0.0% |
| Year Ending | Revenue (£m) |
Pre-tax (£m) |
EPS | P/E | PEG | EPS Growth | Div | Yield |
|---|---|---|---|---|---|---|---|---|
| 2019-09-30 | 0.00 | -12.72 | -3.95p | 0.0 | n/a | 0% | 0.00p | 0.0% |
| 2020-09-30 | 0.00 | -13.10 | -2.64p | 0.0 | n/a | 0% | 0.00p | 0.0% |
| Redx Pharma gets green light to escalate dose in RXC004 study Sharecast News | 19 Aug |
|---|---|
| Redx offloads pan-RAF inhibitor programme to Jazz Pharmaceuticals Sharecast News | 10 Jul |
| Redx Pharma narrows losses as RXC004 trials recommence Sharecast News | 10 Jun |
| First cohort of patients dosed in RXC004 study | 19-Aug-19 07:01 |
|---|---|
| Sale of pan-RAF inhibitor programme | 10-Jul-19 07:03 |